We suggest using a LHRH antagonist (e.g., degarelix) for 6 months starting from day zero of SABR when treating oligometastatic disease in PC to optimise the response to radiotherapy and enable the safe localisation of the target for SABR planning and delivery. Here, GNRH1 is linked to pachyonychia congenita.